NCT07600424 Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea
| NCT ID | NCT07600424 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Brigham and Women's Hospital |
| Condition | Rosacea |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2026-05-23 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2026-05-23 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A single arm, pilot study among individuals with rosacea and at least moderate flushing or rednesss will be enrolled in a 4-week trial of taVNS. The particicpants will be followed for an additional 4-weeks following the intervention period to evaluate the durability of the results
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years of age and older * Dermatologist confirmed diagnosis of rosacea * Clinician's Erythema Assessment of at least 3 (moderate to severe disease) * Willingness to adhere to current rosacea regimen without additions or laser treatments (e.g. PDL) during the study period. Exclusion Criteria: * Changes to rosacea regimen (prescription topical or oral medications) within 4 weeks of randomization. * Facial hair, tattoos, or other characteristics that would interfere with erythema assessments * History of symptomatic cardiac arrythmias (e.g. heart block, sick sinus syndrome, bradyarrhythmia) * Presence of a pacemaker, implanted defibrillator, or neurostimulator * Seizure disorder or epilepsy * Trigeminal Neuralgia within the past year * Severe coronary disease or recent myocardial infarction within the past 5 years * Severe autonomic dysfunction (e.g., frequent syncope, hospitalization) * History of recurrent syncope or unexplained fainting * Use of brimonidine or oxymetazoline within the past 4 weeks * Use of beta-blockers, anticholinergics, or vagal-modulating drugs within the past 4 weeks * Severe phymatous rosacea * Ear deformity, piercings, or other condition that prevents the use of the taVNS device * Known hypersensitivity to electrode materials * Patients who are pregnant.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07600424 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rosacea. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07600424 currently recruiting?
Yes, NCT07600424 is actively recruiting participants. Contact the research team at lchacin@bwh.harvard.edu for enrollment information.
Where is the NCT07600424 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT07600424 clinical trial?
NCT07600424 is sponsored by Brigham and Women's Hospital. The trial plans to enroll 10 participants.